Innoviva Specialty Therapeutics
Clinical trials sponsored by Innoviva Specialty Therapeutics, explained in plain language.
A biopharmaceutical company focused on developing and commercializing respiratory and infectious disease therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New antibiotic under safety watch for hospital superbug
Disease control Recruiting nowThis study is checking how safe the antibiotic sulbactam-durlobactam is for people hospitalized with a hard-to-treat bacterial infection called Acinetobacter baumannii. Researchers will watch 100 participants for about 28 days to see if they have any side effects, especially alle…
Sponsor: Innoviva Specialty Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New antibiotic combo tested in kids to fight superbug infections
Disease control Recruiting nowThis study is testing an antibiotic called Sulbactam-Durlobactam in hospitalized children from birth to under 18 years old who have or may have an Acinetobacter infection. The goal is to find the right dose and check that it is safe. About 48 children will receive the drug throug…
Phase 1 • Sponsor: Innoviva Specialty Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC